Hasni, S., Gupta, S., Davis, M. A., Poncio, E., Temesgen-Oyelakin, Y., Biehl, A., Carlucci, P., Wang, X., Ochoa-Navas, I., Manna, Z. G., Naqi, M., Shi, Y., Thomas, D. E., Chen, J., Biancotto, A., Apps, R., Cheung, F., Kotiliarov, Y., Babyak, A., Stagliano, K., Tsai, W., Vian, L., Gazaniga, N. R., Giudice, V., Playford, M., Brooks, S., Goel, R. R., MacKay, M., Gregersen, P., Diamond, B., Li, X., Remaley, A., Mehta, N., O'Shea, J., Gadina, M., & Kaplan, M. J. (n.d.). 183 A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus. Lupus science & medicine, 6, A139–A140. http://access.bl.uk/ark:/81055/vdc_100144723174.0x000001